BMC Immunology (Feb 2013)

Evaluation of the humoral immune response and cross reactivity against <it>Mycobacterium tuberculosis</it> of mice immunized with liposomes containing glycolipids of <it>Mycobacterium smegmatis</it>

  • Borrero Reinier,
  • García María de los A,
  • Canet Liem,
  • Zayas Caridad,
  • Reyes Fátima,
  • Prieto Jorge L,
  • Infante Juan F,
  • Lanio María E,
  • Kadir Ramlah,
  • López Yamilé,
  • Sarmiento María E,
  • Nor Norazmi Mohd,
  • Acosta Armando

DOI
https://doi.org/10.1186/1471-2172-14-S1-S13
Journal volume & issue
Vol. 14, no. Suppl 1
p. S13

Abstract

Read online

Abstract Mycobacterium smegmatis (Ms) is a nonpathogenic mycobacteria of rapid growth, which shares many characteristics with Mycobacterium tuberculosis (MTB), the major causative agent of tuberculosis. MTB has several cell wall glycolipids in common with Ms, which play an important role in the pathogenesis of tuberculosis and the induction of a protective immune response against MTB infection in some animal models. In this study, the humoral immune response and cross reactivity against MTB, of liposomes containing a mixture of cell wall glycolipids of Ms and commercial lipids was evaluated, in order to study its possible use as a component of a vaccine candidate against tuberculosis. Liposomes containing total lipids extracted from Ms, distearoyl phosphatidyl choline and cholesterol were prepared by the dehydration-rehydration technique. Balb/c mice were immunized with the liposomes obtained and the antibody response and cross reactivity against MTB were tested by ELISA. Total lipids extract from Ms showed the presence of several polar glycolipids in common with MTB, such as phosphatidylinositol mannosides. Liposomes that contained glycolipids of Ms were capable of inducing a specific IgG antibody response that allowed the recognition of surface antigens of MTB. The results of this study demonstrated the presence of immunogenic glycolipids in Ms, which could be included to enhance the protective effects of subunit vaccine formulations against tuberculosis.